These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 6134657)
1. [Pharmacological studies on oxatomide. (5). Effect on the central and peripheral nervous systems]. Ohmori K; Ishii H; Shuto K; Nakamizo N Nihon Yakurigaku Zasshi; 1983 Mar; 81(3):245-66. PubMed ID: 6134657 [TBL] [Abstract][Full Text] [Related]
2. General pharmacological properties of the new vasodilator flosequinan. Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141 [TBL] [Abstract][Full Text] [Related]
3. General pharmacological properties of the main metabolite of flosequinan. Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacological studies on oxatomide: (6) Effect on the peripheral organs]. Ohmori K; Ishii H; Shuto K; Nakamizo N Nihon Yakurigaku Zasshi; 1983 Jan; 81(1):79-104. PubMed ID: 6133821 [TBL] [Abstract][Full Text] [Related]
5. [Effects of suloctidil on the central and peripheral nervous systems]. Nishi H; Watanabe T; Mori M Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacological studies on oxatomide (KW-4354). (7) Antagonistic effects on chemical mediators]. Ohmori K; Ishii H; Nito M; Shuto K; Nakamizo N Nihon Yakurigaku Zasshi; 1983 May; 81(5):399-409. PubMed ID: 6138301 [TBL] [Abstract][Full Text] [Related]
7. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human). Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems. Hirohashi M; Takasuna K; Kasai Y; Usui C; Kojima H Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569 [TBL] [Abstract][Full Text] [Related]
9. [Effects of ritodrine hydrochloride on motor nervous system and central nervous system]. Ikeda S; Tsukamoto T Nihon Yakurigaku Zasshi; 1984 Sep; 84(3):311-26. PubMed ID: 6500405 [TBL] [Abstract][Full Text] [Related]
10. General pharmacological profile of the new cognition-enhancing agent nefiracetam. Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090 [TBL] [Abstract][Full Text] [Related]
11. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide. Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167 [TBL] [Abstract][Full Text] [Related]
12. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system. Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380 [TBL] [Abstract][Full Text] [Related]
13. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system. Shintani S; Toba Y; Suzuki S; Ninomiya S; Umezato M; Hiyama T Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. III: Effects on the central nervous system, striated muscle and carbohydrate and lipid metabolism. Osada E; Sakaya S; Sanai K; Seri K Arzneimittelforschung; 1984; 34(11A):1652-8. PubMed ID: 6152158 [TBL] [Abstract][Full Text] [Related]
15. General pharmacology of the new quinolone antibacterial agent levofloxacin. Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443 [TBL] [Abstract][Full Text] [Related]
16. General pharmacological profile of the new anti-ulcer drug 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]-amino-N -methylbenzamide. Hirohashi M; Takasuna K; Kasai Y; Usui C; Tamura K; Kojima H Arzneimittelforschung; 1993 May; 43(5):569-77. PubMed ID: 8329002 [TBL] [Abstract][Full Text] [Related]
17. General pharmacology of recombinant human basic fibroblast growth factor. Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346 [TBL] [Abstract][Full Text] [Related]
18. Dissociation between central and peripheral antihistamine activities of the new antiallergic agent N-[4-[4-(diphenylmethyl)-1-piperazinyl]-butyl]-3-(6-methyl-3-pyridyl) acrylamide in rats and monkeys. Ishii K; Yakuo I; Nakagawa H; Nakamura H Arzneimittelforschung; 1993 Jun; 43(6):668-71. PubMed ID: 8102529 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological studies on timiperone, a new neuroleptic drug Part II: General pharmacological properties. Yamasaki T; Kojima H; Tanaka M; Aibara S; Hirohashi M; Kasai Y; Tsubokawa M; Watanabe K; Akashi A Arzneimittelforschung; 1981; 31(4):707-15. PubMed ID: 6113834 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacological actions of oxatomide (KW-4354). 3. Actions on experimental asthma and Schultz-Dale reaction]. Ohmori K; Ishii H; Takei Y; Shuto K; Nakamizo N Nihon Yakurigaku Zasshi; 1982 Dec; 80(6):481-93. PubMed ID: 6131021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]